Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
In Japan, the 2016 Clinical Practice Guideline for the Management of Renal Injury during Cancer Chemotherapy weakly recommended magnesium (Mg) supplementation to prevent cisplatin (CDDP)–induced acute kidney injury (AKI). However, the extent of its real-world implementation has not been well investigated, and CDDP-induced AKI continues to occur in patients without Mg supplementation. This study aimed to clarify the current status and temporal trends of Mg supplementation in patients receiving CDDP at Hamamatsu University Hospital and to identify issues related to its implementation.
This retrospective study included adult patients (≥18 years) registered in the clinical database of Hamamatsu University Hospital (Shizuoka, Japan) who received CDDP between 2008 and 2024. We assessed the number and proportion of patients administered magnesium sulfate on the day of their first CDDP treatment.
A total of 2,685 patients received CDDP during the study period, and 689 patients were prescribed magnesium sulfate. Before publication of the 2016 guideline, the Mg supplementation rate was 0.0% in 2008–2012 and 5.7–12.8% in 2013–2015. Following the guideline’s release, the rate increased to 22.6–37.8% during 2016–2021, though remaining below 50%. The rate subsequently rose to 62.0% in 2022, 76.4% in 2023, and 83.9% in 2024. The publication of the second edition of the guideline in 2022, together with refinement of chemotherapy regimens, likely contributed to this improvement.
At our Japanese tertiary care hospital, Mg supplementation among patients receiving CDDP markedly increased beginning in 2022. However, the supplementation rate remains around 80%, indicating that implementation is still insufficient. Further analyses, including Mg monitoring rates and department-specific supplementation trends, are ongoing and will be reported in detail. This abstract was also submitted for the 46th Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics congress.
